Abstract: This invention relates to methods of treating and ameliorating congenital and neonatal hyperinsulinism and post-prandial hypoglycemia, comprising the step of administering an antagonist of the Glucagon-Like Peptide-1 (GLP-1) receptor, e.g. a GLP-1 fragment or analogue thereof.

Abstract: The present disclosure is directed to antibodies binding to Glypican 2 and methods of using such antibodies to treat cancers that express or overexpress the Glypican 2 antigen.

Abstract: The present disclosure relates to recombinant adeno-associated vims (rAAV) delivery of a neurotrophin 3 (NT-3) polynucleotide. The disclosure provides rAAV and methods of using the rAAV for NT-3 gene therapy to improve muscle strength, stimulate muscle growth and to treat muscle wasting disorders, such as muscular dystrophy and Charcot-Marie-Tooth neuropathy.

Abstract: Methods for diagnosing and treating conduct disorder are encompassed, wherein diagnosis and treatment may be based upon an assessment of genetic alterations in metabotropic glutamate receptor (mGluR) network genes and wherein treatment is with nonspecific activators of mGluRs such as fasoracetam.

Abstract: This disclosure provides isolated or recombinant polypeptides that are useful to vaccinate individuals suffering from chronic/recurrent biofilm disease or as a therapeutic for those with an existing infection. The individual's immune system will then naturally generate antibodies which prevent or clear these bacteria from the host by interfering with the construction and or maintenance of a functional protective biofilm. Alternatively, antibodies to the polypeptides can be administered to treat or prevent infection. Bacteria that are released from the biofilm by our technology are more readily cleared by the remainder of the host's immune system.

Abstract: In Hybrid and truncated immune cell proteins are described. Hybrid proteins are stimulatory and include an extracellular domain of one stimulatory immune cell protein, an intracellular domain of a different stimulatory immune cell protein, and a transmembrane domain linking the extracellular domain to the intracellular domain. Truncated proteins include an immune cell receptor ligand and a transmembrane domain but lack a functional intracellular domain. The hybrid and truncated proteins can be used to modulate and/or diversify immune cell activation in the fight against cancers and infectious diseases, among other uses.

Abstract: A frequency encoded source imaging system includes an EEG or MEG sensor array and a processing system for analyzing the signals from the sensor array in at least two different frequency bands, where the analysis is localized with respect to a three-dimensional grid corresponding to the portion of the human body. Alternately, a frequency encoded source imaging system includes an EEG or MEG sensor array and a processing system for analyzing the signals from the sensor array in a high-definition frequency band comprising frequencies greater than 70 Hz, where the analysis is localized with respect to a three-dimensional grid corresponding to the portion of the human body.

Abstract: Provided herein are methods and kits for collecting and/or detecting biological materials from the skin of subjects. Methods and kits for determining a biological profile of a target skin site of subjects are also provided herein.

Abstract: A simulation method for a chronic atrophic gastritis (CAG) lesion includes: (1) taking a metaplasia lesion stage as a simulation object, (2) selecting a simulation form of spasmolytic polypeptide-expressing metaplasia (SPEM), and (3) conditionally deleting gene associated with retinoid-IFN-induced mortality-19 (GRIM-19) from gastric mucosal parietal cells. The present disclosure successfully simulates the SPEM, an initial metaplasia response after a gastric mucosal injury and the initial metaplasia response can progress into intestinal metaplasia (IM) and even gastric cancer (GC) under the continuous stimulation of chronic inflammation.

Abstract: The disclosure provides for methods of predicting disease progression comprising detecting a modification of one or more disease markers in a glial cell or neuronal cell generated from a skin cell of the subject. The disclosed methods include methods of identifying subjects that are responsive to a therapeutic agent and methods of determining effectiveness of a therapeutic agent.

Abstract: The present disclosure is directed to methods of utilizing echocardiography for assessing hemodynamic significance of patent ductus arteriosus (PDA) at early time points to supplement a patient's clinical and laboratory data by determining a PDA severity score. The present disclosure is further directed to treating the patient for PDA based on the severity score.

Abstract: The invention relates to modified Factor IX coding sequence, expression cassette, vectors such as viral (e.g., lenti- or adeno-associated viral) vectors, and gene transfer methods and uses. In particular, to target Factor IX nucleic acid to cells, tissues or organs for expression (transcription) of Factor IX.

Abstract: Hematopoietic stem/progenitor cells (HSPC) and/or non-T effector cells are genetically modified to express (i) an extracellular component including a ligand binding domain that binds a cellular marker preferentially expressed on an unwanted cell; and (ii) an intracellular component comprising an effector domain. Among other uses, the modified cells can be administered to patients to target unwanted cancer cells without the need for immunological matching before administration.

Abstract: Compositions for the identification of patients at risk for the development of latent autoimmune diabetes, and methods of use thereof, for the diagnosis and treatment of the same.

Abstract: An orthopaedic device for securing between first and second regions of bone separated by a growth plate, the orthopaedic device comprising: a first portion to secure to a first fixing location on the first bone region; a second portion to secure to a second fixing location on the second bone region, the first fixing location and the second fixing location being laterally offset relative to a longitudinal axis of the bone; wherein the first and second portions are pivotally coupled between a first coupling location on the first portion and a second coupling location on the second portion such that movement of the first and second portions away from each other in a direction parallel to the longitudinal axis of the bone causes relative rotation of the first bone region and the second bone region thereby reducing the lateral offset of the first location and the second location.

Abstract: Disclosed herein are virus-like particle (VLP)-based bivalent vaccine compositions. The compositions may comprise a spherical retroviral Group-specific Antigen (“Gag”) protein core and at least two Ebola glycoproteins. The at least two Ebola glycoproteins may be located at the exterior surface of the spherical Gag protein core, such that the VLP-based vaccine presents at least two Ebola glycoprotein antigens. In one aspect, the at least two Ebola glycoproteins are a Zaire (EBOV) glycoprotein, and a Sudan (SUDV) glycoprotein.

Abstract: A system for guiding a medical intervention is disclosed. The system employs a device guide that operates on the surface of a sphere that is centered on a selected target.

Abstract: A biometric sensor device system including a biometric sensor device, and a prediction computer. The biometric sensor device includes at least one camera, and a biometric sensor device processor configured to record a time synchronized communicative interaction between participants, by controlling at least one camera to record the participants over a time period, and transfer the recorded communicative interaction to the prediction computer. The prediction computer including a prediction computer processor configured to extract, from the recorded communicative interaction, a physical characteristic of each of the participants over the time period, compare the physical characteristic of at least one of the participants with the physical characteristic of at least another one of the participants over the time period, and classify or score at least one of the participants according to a predetermined classification or dimensional scoring scheme based on the comparison.

Abstract: A transcranial scanning device and method of use is disclosed. The transcranial scanning device is for identifying a neurologic-injury-mechanism and comprises a sensing wand comprising a transducer that produces and receives sound waves. The sensing wand is passed over a head of a patent with cerebral malaria, and sound waves reflect off of blood cells in blood vessels in the head of the patient creating an output sound wave responsive to a blood flow of the patient. The output sound wave is received by the transducer. An output screen coupled to the sensing wand, displays in real time an output waveform corresponding to the output sound wave, wherein the output waveform is indicative of one or more symptoms of cerebral malaria, and wherein said symptoms identify one or more neurologic-injury-mechanism occurring within the patient.

Abstract: The present disclosure relates to biomarker profiles and their use to predict a subject's response to an immunomodulatory treatment. Biomarkers in these profiles include cytokines and other proteins associated with the interleukin 1 family and the type 1 interferon family. Particular biomarkers include interleukin (IL)-2, soluble IL-2 receptor alpha (sIL-2RA), IL-5, IL-6, IL-9, IL-10, IL-18, IL-18 binding protein (IL-18BP), IL-18 receptor 1 (IL-18R1), IL-18 receptor accessory protein (IL-18RAP), IL-22, C-type lectin-like receptor (CD161), CD56, interferon gamma (IFN?), granulocyte macrophage colony stimulating factor (GM-CSF), serum amyloid A (SAA), and C-reactive protein (CRP). Particular biomarkers also include populations of cells including CD161+ cells and CD56+dim cells. The biomarker profiles can be used to predict a subject's responsiveness to an immunomodulatory treatment (e.g.